Esperion announced the expansion of its development portfolio with a new program aimed at treating primary sclerosing cholangitis (PSC), a rare liver disease. The company confirmed the effectiveness ...
Data demonstrate that ATV-1601, a selective allosteric inhibitor of AKT1 E17K, provides enhanced target inhibition, superior efficacy and improved tolerability compared to pan-AKT inhibitors in ...
WALTHAM, Mass.--(BUSINESS WIRE)--Ensem Therapeutics, Inc. (ENSEM), a pioneering drug discovery and development company that leverages its unique Kinetic Ensemble® platform to advance innovative small ...
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize ...
The MarketWatch News Department was not involved in the creation of this content. - Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and sustained hematologic ...
RAS is the most mutated oncogene in cancer (about 30% rate), where mutations in KRAS are the most prevalent. The approval of covalent KRAS G12C inhibitors has shown allosteric inhibition of KRAS to be ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Neuron23 ® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological ...
Relay Therapeutics leads with RLY-2608, an allosteric PI3Kα inhibitor showing superior safety and efficacy in advanced breast cancer. RLY-2608’s phase 1/2 trial data demonstrates higher response rates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback